302 results about "Nicotinamide mononucleotide" patented technology

The invention relates to the technical field of biomarkers, in particular to a blood biomarker combination for prediction and auxiliary diagnosis of ovarian reserve hypofunction (DOR), a corresponding detection kit and application of the blood biomarker combination. According to the invention, the content change of the nicotinamide mononucleotide (NMN) and the metabolite combination thereof in serum or plasma is screened for the first time and can be used as a detection index for predicting the ovarian reserve function decline. Based on the biomarker combination, the invention further provides an in-vitro detection kit containing a related standard substance, an internal standard solution and an extracting solution, and a data analysis method combined with a random forest model, so that an individual with a normal ovarian reserve function and an individual with hypofunction can be accurately distinguished. The method is noninvasive, simple, convenient, high in sensitivity and suitable for early recognition and layered screening of clinical ovarian reserve hypofunction.

The invention belongs to the field of nano preparations, and discloses a preparation method of nano microspheres coated with a nicotinamide mononucleotide shell membrane structure, which comprises the following steps: coating NMN in a pregel formed by chitosan and sodium tripolyphosphate, heating and stirring, adjusting the pH value to separate out chitosan-coated nano microspheres, drying to remove moisture on the surfaces of the nano microspheres, and drying to obtain the nano microspheres coated with the nicotinamide mononucleotide shell membrane structure. Then selecting a water phase and an oil phase in a proper proportion, preparing a chitosan / sodium alginate composite nano-microsphere with sodium alginate as an outer membrane by adopting an emulsion cross-linking method, and washing and drying to obtain the NMN nano-microsphere with a core-shell structure. According to the invention, NMN is coated in the nano-microsphere which is composed of two materials and has a nuclear membrane structure, so that the stability of NMN in a natural environment can be improved, hydrolysis of NMN by gastric acid and gastrointestinal tract enzyme in a drug delivery process can be prevented, the bioavailability of NMN is improved, and a drug sustained release effect is achieved.

The invention provides anti-aging moisturizing essence and a preparation method thereof, and belongs to the technical field of cosmetics. The essence is prepared from a plant extract, sodium pyrrolidone carboxylate, hexapeptide, nicotinamide mononucleotide, vitamin B5, galactose yeast fermentation product filtrate, b-glucan, sodium hyaluronate, glycerol, tranexamic acid, blue copper peptide, arbutin, nicotinamide, vitrin, a bifidus yeast fermentation product, a bifidus yeast fermentation lysate and the like. Wherein the plant extract is prepared by mixing rosemary, frankincense resin, tea flowers, sandalwood and jasmine flowers through ultrasonic extraction, comprehensive skin care is achieved from multiple angles of anti-aging, whitening, moisturizing and repairing, the overall health of the skin is guaranteed, and the skin care cream is suitable for various skin types.

The invention relates to the technical field of biology, in particular to a recombinant strain for producing nicotinamide mononucleotide and application of the recombinant strain. According to the method, accumulation of the NMN is improved through metabolic flux redirection and gene knockout, a synthesis path of the NMN is successfully established in escherichia coli, and further, the yield of the NMN is effectively improved and reaches 7.0 g / L by optimizing a transport system of NAM-NMN and a PRPP synthesis path. The invention also optimizes the production process of the NMN, realizes the highest yield of the NMN of 28.5 g / L in a fed-batch fermentation system, and obviously improves the yield compared with the traditional batch fermentation.

The invention belongs to the technical field of bioengineering, and particularly relates to a polyphosphate kinase mutant and application thereof in synthesis of beta-nicotinamide mononucleotide, and the polyphosphate kinase mutant is obtained by single-point or multi-point mutation of 99th, 186th, 190th and 204th amino acids of polyphosphatase with an amino acid sequence shown as SEQ ID NO.1. The invention also relates to a preparation method of the polyphosphate kinase mutant, and the application of the polyphosphate kinase mutant in synthesis of beta-nicotinamide mononucleotide in synthesis of beta-nicotinamide mononucleotide in synthesis of beta-nicotinamide mononucleotide in synthesis of beta-nicotinamide mononucleotide. Polyphosphokinase derived from Lampropedia Hyalina DSM 16112 is subjected to molecular modification to obtain multiple mutants, the enzyme activity of the mutants is improved by 1.5-14 times compared with that of wild type polyphosphokinase, the preference of the mutants to AMP is improved by 1.08-4.88 times compared with that of the wild type polyphosphokinase, and an ATP regeneration system constructed by the mutants can remarkably reduce the use amount of enzyme and reduce the fermentation capacity and cost; the reaction time can be greatly shortened, the influence of AMP on the enzyme activity is reduced, the requirements of large-scale industrial production of NMN prepared by adopting a biological enzyme method can be met, and the method has a wide application prospect.

A nutraceutical composition, consisting of Nicotinamide Mononucleotide in a range 250-1000 mg, Spermidine in a range 0.5-10 mg, Rhodiola Rosea in a range 200-600 mg, Cacao in a range 1000-10,000 mg, L-Theanine in a range 50-200 mg, Glucosamine in a range 500-3000 mg, and Hyaluronic acid in a range 50-240 mg, or consisting of Epigallocatechin-3-gallate in a range 100-500 mg, Quercetin in a range 250-1000 mg, Resveratrol in a range 150-1000 mg, Sulforaphane in a range 1-50 mg, and Calcium Alphaketoglutarate in a range 300-2000 mg, or consisting of Microdose Lithium in a range 1-5 mg, Trimethylglycine in a range 500-2000 mg, Glutathione in a range 250-1000 mg, Fisetin in a range 100-1000 mg, Urolithin A in a range 250-2000 mg, Sodium Butyrate in a range 100-3000 mg, Berberine in a range 500-1500 mg, Apigenin in a range 50-500 mg, Cinnamon in a range 1000-6000 mg, and Malate in a range 1000-6000 mg.

The invention provides a nicotinamide phosphoribosyltransferase mutant and an application of the nicotinamide phosphoribosyltransferase mutant in preparation of beta-nicotinamide mononucleotide. According to the nicotinamide phosphoribosyltransferase mutant, 259th lysine (K) of an amino acid sequence shown in SEQ ID NO: 2 is mutated into 259th valine (V). The invention overcomes the technical problems of slow reaction, low yield, high energy consumption and NMN feedback inhibition of the product in the process of producing NMN by escherichia coli, and the constructed nicotinamide phosphoribosyltransferase mutant expression system is used for fermentation production of nicotinamide mononucleotide, and slows down the feedback inhibition effect.

The invention discloses a double-ligand Eu-MOF and application thereof in detection of nicotinamide mononucleotide, and belongs to the technical field of analysis and detection. The preparation method of Eu-TATB-BDC-NH2 comprises the following steps: dissolving 2, 4, 6-tri (4-carboxyphenyl)-1, 3, 5-triazine, 2-aminoterephthalic acid and europium nitrate hexahydrate in a mixed solution of water and N, N-dimethylformamide (DMF), adding nitric acid to adjust the pH value, ultrasonically dispersing uniformly, reacting in a high-pressure reaction kettle (polytetrafluoroethylene lining), cooling, centrifuging, washing and drying to obtain pink solid Eu-TATB-BDC-NH2; when the Eu-MOF is used for detecting the NMN, the method is simple, convenient, rapid and high in sensitivity, and a new strategy is provided for detecting the NMN in an actual sample.

The invention relates to a compound NMNH calcium salt, in particular to an amorphous form of a reduced β-nicotinamide mononucleotide calcium salt, a preparation method therefor, a use thereof as a pharmaceutical ingredient, a health care product ingredient and a cosmetic ingredient or as a food additive, and a formulation containing the salt, belonging to the field of medicines, health care products, cosmetics and food additives. Specifically, described in the invention is a NMNH calcium salt amorphous compound. The compound shows long-term continuous stability, and compared with NMNH disodium salt, has significantly superior oxidation resistance and stability, and anti-hygroscopic properties, and is more beneficial to long-term storage, promotion and market application. The NMNH calcium salt amorphous compound is simple in preparation process, easy to control and suitable for large-scale production.

The invention is applied to agricultural production, and particularly relates to a biostimulant formula and application of the biostimulant formula in promoting or regulating crop growth and inducing disease resistance in agricultural production. The biostimulant active component contains lactulose and nicotinamide mononucleotide; wherein the weight ratio of lactulose to nicotinamide mononucleotide is (1-10): (1-10). The formula of the biostimulant has the functions of promoting crop growth, improving crop quality and inducing disease resistance at the same time. The raw materials required by the formula are low in price and easy to obtain, the preparation process is simple, the equipment requirement is low, and the formula can be applied to the field of agricultural production.

The invention relates to a natural plant functional component based on cell function regulation, a natural plant composition and application thereof. The natural plant composition is prepared from the following raw material components in parts by weight: 1000 to 1600 parts of phospholipid, 200 to 400 parts of cholesterol, 200 to 400 parts of prinsepia utilis royle oil, 100 to 300 parts of ergothioneine and 200 to 500 parts of nicotinamide mononucleotide. Compared with the prior art, the composition not only can cover multi-target composite components with ROS removal, mitochondrial autophagy activation and NAD + level improvement, but also can improve the component permeability by optimizing the delivery technology, thereby effectively improving the skin anti-aging effect and the like.

The invention relates to a compound NMNH calcium salt, in particular to an amorphous form of a reduced β-nicotinamide mononucleotide calcium salt, a preparation method therefor, a use thereof as a pharmaceutical ingredient, a health care product ingredient and a cosmetic ingredient or as a food additive, and a formulation containing the salt, belonging to the field of medicines, health care products, cosmetics and food additives. Specifically, described in the invention is a NMNH calcium salt amorphous compound. The compound shows long-term continuous stability, and compared with NMNH disodium salt, has significantly superior oxidation resistance and stability, and anti-hygroscopic properties, and is more beneficial to long-term 10 storage, promotion and market application. The NMNH calcium salt amorphous compound is simple in preparation process, easy to control and suitable for large-scale production.

The invention discloses a targeted energy metabolism composition for improving the anti-aging effect of skin as well as a preparation method and application of the targeted energy metabolism composition. The targeted energy metabolism composition is prepared from the following components in parts by mass: 0.1 to 5 parts of saccharomycetes rice fermentation filtrate, 0.1 to 5 parts of a tremella aurantialba sporocarp extract and 0.01 to 5 parts of nicotinamide mononucleotide NMN liposome. According to the targeted energy metabolism composition for improving the anti-aging effect of the skin and the preparation method and application of the targeted energy metabolism composition, effective permeation and precise delivery of functional components can be achieved, and the anti-aging, whitening and moisturizing effects of the skin are improved.

The invention relates to crystalline forms of a β-nicotinamide mononucleotide, methods of their preparation, and related pharmaceutical preparations thereof. The invention also relates to preparations suitable for nutraceutical, veterinary, and agriculturally-relevant uses.

The invention relates to an application of beta-nicotinamide mononucleotide (NMN) in prevention and treatment of liver injury caused by aflatoxin B1 (AFB1), the NMN has a good protection effect on the liver injury caused by exposure of the AFB1, and particularly, the serum transaminase activity and liver tissue pathological injury of a mouse using an NMN + AFB1 group are improved compared with those of a mouse in the AFB1 group, and the NMN has a good protection effect on the liver injury caused by exposure of the AFB1 group. Namely, the NMN has a certain protection effect on the mouse liver injury induced by exposure of the AFB1; the content of IL-6, IL-1beta and TNF-alpha in the liver of a mouse in an AFB1 group is remarkably increased, and the expression of IL-6, IL-1beta and TNF-alpha in the liver of the mouse infected with AFB1 is remarkably reduced by the NMN, namely, the NMN relieves the inflammatory response induced by the AFB1. The NMN can effectively relieve the development of mouse AFB1 subchronic poisoning and gradually recover the mouse AFB1 subchronic poisoning to a normal level, so that a new clue and an experimental basis are provided for research and development of an additive or a medicine for resisting AFB1 poisoning.

The invention relates to the technical field of pharmaceutical preparations, and discloses a biological beauty skin care product containing nicotinamide adenine dinucleotide (NAD < + >) and cell exosomes, and the biological beauty skin care product comprises the following components by weight: 10-50 parts of a pH responsive nicotinamide mononucleotide liposome; 1 to 10 parts of cell exosome sustained release microspheres; 0.1 to 2 parts of ergothioneine; 0.1 to 1 part of copper peptide; 1 to 10 parts of phytosphingosine; 0.01 to 0.5 part of water-soluble fullerene; 1-8 parts of 1, 2-pentanediol as a transdermal enhancer; 0.05 to 0.5 part of acetylated polypeptide-8; wherein the particle size of the pH response type nano-liposome is 50-200 nm, and the particle size of the hyaluronic acid microspheres is 100-500 nm, so that the skin health is promoted, and the metabolic function is regulated.

The invention discloses a method for detecting the content of nicotinamide mononucleotide, ergothioneine and nicotinamide. According to the method, the content of nicotinamide mononucleotide, ergothioneine and nicotinamide in a sample is analyzed by adopting a high performance liquid chromatography; according to the method, a CAPCELL PAK ADME chromatographic column is used, and the molecular weight of the CAPCELL PAK ADME chromatographic column is 100 And an acetonitrile-buffer solution is used as a mobile phase. Chromatographic peaks obtained by the method are sharp and symmetrical in shape, good in area reproducibility, good in separation degree, simple, rapid, high in specificity, short in detection period and high in sensitivity; the contents of nicotinamide mononucleotide, ergothioneine and nicotinamide in a sample can be rapidly, efficiently, accurately and simultaneously detected.

The utility model discloses a raw material oscillation device for beta-nicotinamide mononucleotide production, and belongs to the technical field of beta-nicotinamide mononucleotide production. The raw material oscillation device for beta-nicotinamide mononucleotide production comprises an oscillation base and an oscillation platform, a fixing plate is arranged in the oscillation base, a driving motor is installed below the fixing plate, the output end of the driving motor is connected with a hexagonal shaft, the hexagonal shaft is sleeved with a rotating disc, and a first wave face is arranged on the lower surface of the rotating disc. According to the raw material oscillation device for beta-nicotinamide mononucleotide production, the driving motor controls the rotating disc to rotate, under the action of the first wave surface, the second wave surface, the first limiting ball and the second limiting ball, vertical vibration and multidirectional inclined superposition are achieved, jolting and swinging composite motion is formed, the actually measured mixing uniformity is improved, and the production efficiency is improved. The wave crest number of the first wave surface is integral multiples of the number of the first limiting balls, so that the vertical vibration synchronism is ensured.

The present invention discloses the use of a nonspecific 5'-nucleotidase in the preparation of nicotinamide riboside. The nonspecific 5'-nucleotidase is selected from a nonspecific 5'-nucleotidase derived from Shewanella sp. HN-41. The nonspecific 5'-nucleotidase of the present invention can efficiently catalyze the hydrolysis of high-concentration nicotinamide mononucleotide (NMN) to produce nicotinamide riboside (NR), exhibits high enzymatic activity, and has value for industrial application.

The invention relates to an anti-aging capsule compounded by PQQ and mitochondrial nutrients, and discloses an anti-aging capsule which is prepared by synergistically compounding a plurality of mitochondrial nutrients according to a scientific proportion and supplementing high-purity raw materials and slow-release dosage forms to realize energy metabolism activation and anti-oxidation synergistic intervention. Therefore, the anti-aging capsule systematically delays aging through multi-target regulation and control of mitochondrial functions. The capsule is characterized by comprising the following components in parts by weight: 1-20 mg of pyrroloquinoline quinone disodium salt (PQQ), 20-100 mg of coenzyme Q10, 50-200 mg of L-carnitine tartrate, 10-100 mg of alpha-lipoic acid, 50-300 mg of nicotinamide mononucleotide (NMN) or nicotinamide nucleoside (NR), and 10-50 [mu] g of selenoprotein or organic selenium yeast, and a capsule carrier comprises 100 mg of gelatin or a plant-derived capsule shell, 180 mg of microcrystalline cellulose, 5 mg of magnesium stearate and 5 mg of silicon dioxide.

The invention relates to a compound NMNH calcium salt, in particular to an amorphous form of a reduced beta-nicotinamide mononucleotide calcium salt, a preparation method of the reduced beta-nicotinamide mononucleotide calcium salt, application of the reduced beta-nicotinamide mononucleotide calcium salt as a pharmaceutical ingredient, a health care product ingredient, a cosmetic ingredient or a food additive, and a preparation containing the reduced beta-nicotinamide mononucleotide calcium salt, and belongs to the field of medicines, health care products, cosmetics and food additives. Specifically, the invention describes an amorphous compound of NMNH calcium salt, the compound shows long-term continuous stability, the oxidation resistance, the stability and the moisture absorption resistance of the compound are obviously superior to those of NMNH disodium salt, and the compound is more beneficial to long-term storage, popularization and marketing. The preparation process of the NMNH calcium salt amorphous compound is simple, easy to control and suitable for large-scale production.

The present application relates to a preservative-free anti-aging soothing composition containing high mountain plant extract and multiple fermentation filtrate, belonging to the technical field of cosmetics. The composition comprises high mountain plant extract complex, multiple fermentation filtrate, anti-aging active and vegetable oil. The organic acids in the multiple fermentation filtrate form a natural buffer system, maintaining a weakly acidic environment to inhibit microbial growth; at the same time, the natural components in the fermentation filtrate provide protection for nicotinamide mononucleotide and ergothioneine, delaying their degradation. The present application does not need to add additional preservatives, and has the functions of anti-aging, soothing and self-preserving.

The invention discloses application of beta-nicotinamide mononucleotide in regulation and control of gene editing efficiency, belongs to the field of gene editing treatment, and finds that the beta-nicotinamide mononucleotide (NMN) can efficiently inhibit the activity of CRISPR-Cas9, CRISPR-Cas12 and CRISPR-Cas13 systems in a broad-spectrum manner for the first time. The application comprises emergency blocking of off-target effect in gene editing clinical treatment, biological safety prevention and control of a virus vector gene editing system, and CRISPR activity regulation and control of in-vitro non-diagnostic purpose. Experiments show that NMN can inhibit CRISPR-mediated gene damage and cell death in a cell model, the inhibition efficiency in an in-vitro enzyme digestion system reaches 68.7%, and cell growth or transfection efficiency is not affected. The invention provides an innovative solution for safe application of CRISPR (clustered regularly interspaced short palindromic repeats) technology, and the NMN is approved to be taken orally as a health care product, so that the NMN has extremely strong clinical application potential. Compared with the existing CRISPR (clustered regularly interspaced short palindromic repeats)-resistant protein or synthetic small-molecule inhibitor, the NMN has the advantages of endogenous property, high biocompatibility, good oral safety and the like.

The present application relates to the technical field of biological medicine, and in particular to a cat triple vaccine immune adjuvant containing two kinds of cat interleukins and metabolic regulatory molecules, a composition and application. The composition comprises cat interleukin 15, cat interleukin 23 and a metabolic regulatory molecule, the metabolic regulatory molecule comprises beta-nicotinamide mononucleotide, beta-nicotinamide adenine dinucleotide disodium salt, N-acetyl cysteine and L-carnitine, and can be used for preparing a cat triple vaccine or an auxiliary preparation of the cat triple vaccine. The composition can effectively improve the protection of the vaccine, prolong the protection time of the vaccine and reduce adverse reactions; the vaccine can more durably and at a higher level reduce or control the reproductive infection of viruses, significantly improve the specific humoral immune level and memory response ability of animals, and better resist the invasion and spread of FPV, FCV and FHV-1.

The present invention relates to a compound, NMNH calcium salt, and more particularly to an amorphous reduced β-nicotinamide mononucleotide calcium salt, its preparation method, its use as pharmaceutical and cosmetic ingredients, and preparations containing these salts, belonging to the fields of medicine and cosmetics. Specifically, the present invention describes an amorphous NMNH calcium salt compound that exhibits long-term stability, significantly superior antioxidant properties, stability, and hygroscopic resistance to the disodium NMNH salt, and is more suitable for long-term storage and market promotion. The amorphous NMNH calcium salt compound has a simple preparation process, is easily controlled, and is suitable for large-scale production.

The present invention addresses the problem of defining physiological significance and functions such as the influence of nicotinamide mononucleotide (NMN) contained in breast milk on the development of children. A composition for improving the athletic ability of a child is provided comprising a precursor of NAD. The improvement in athletic ability is preferably any one selected from the group consisting of promotion of skeletal muscle development and improvement in activity. A composition for reducing triglyceride levels in the blood of a child is provided comprising a precursor of NAD. A composition for reducing the blood glucose level in a child is provided comprising a precursor of NAD. A composition for inhibiting fat accumulation in children is provided, comprising a precursor of NAD.

The invention relates to the technical field of medical supplies, and particularly provides an NMN-containing circulation promoting and skin aging resisting repair patch which comprises a repair liquid and a non-woven fabric, the repairing liquid is prepared from the following raw materials in percentage by weight: 0.2 to 0.5 percent of sodium hyaluronate, 0.01 to 0.2 percent of beta-nicotinamide mononucleotide (NMN), 2 to 4 percent of glycerol, 0.5 to 1.5 percent of propylene glycol, 0.005 to 0.015 percent of ethylene diamine tetraacetic acid disodium salt, 0.015 to 0.03 percent of ethylparaben, 1 to 2 percent of sodium carboxymethyl cellulose, 0.05 to 2.0 percent of triethanolamine and the balance of purified water. The repair patch has good moisture retention, stability and oxygen permeability, and is small in irritation.

An object of the present disclosure is to provide a novel animal nutritional composition. The disclosure is directed to a racehorse nutritional composition, an animal nutritional composition for reducing an elevation of blood lactic acid concentrations, and an animal nutritional composition for coat improvement, each of which contains nicotinamide mononucleotide.

The present invention provides a strain of Escherichia coli resistant to nicotinamide stress and its application, which belongs to the field of microbial engineering technology. The strain is Escherichia coli AE74, which has been deposited in the China Center for Type Culture Collection on December 23, 2022, with a deposit number of CCTCC NO: M 20222059. The strain resistant to nicotinamide (NAM) stress has both excellent anti-nicotinamide performance and high nicotinamide mononucleotide (NMN) yield. On the one hand, under non-nicotinamide stress conditions, strain AE74 has a higher NMN yield than the starting strain. On the other hand, strain AE74 overcomes the problem of low NAM tolerance of the starting strain, and can maintain a high survival rate and NMN yield at high NAM concentrations, providing a new strain with high NMN yield suitable for industrial production.

The present invention comprises (i) or (ii). (i) Golden oyster mushroom or a processed product thereof. (ii) Nicotinamide mononucleotide and 5-deazaflavin.